Best Genitourinary Disorders Companies in United States
The 162 best Genitourinary Disorders companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Barinthus Biotherapeutics.
The 162 Genitourinary Disorders companies tracked in the United States represent $2.8B in disclosed funding, and this directory ranks them by equity raised and recent funding momentum. No unicorns yet. But the capital is real, and it's moving. VenatoRx leads the field at $103M raised, with Bright Uro at $65M and Rivermark at $34M rounding out the top tier. The global market sits at roughly $32.6B as of 2021, forecast to reach $37.0B by 2027 at a 2.11% CAGR, driven by aging populations, rising urinary incontinence rates, and a deepening pipeline. That steady, if unspectacular, growth rate tells you this isn't a moonshot sector. It's a durable one.
So what's actually pulling investment dollars in? Hot coverage themes right now cluster tightly around prostate health: biopsy tech, inflammation, age-related cancer screening, ultrasound diagnostics. Backers like HHS, NIH, and Google Ventures are active across the 162 companies I track here, which signals both clinical legitimacy and commercial interest. One structural drag worth noting: the absence of a predefined regulatory framework for some therapeutic categories creates real compliance uncertainty for smaller filers. Still, if you're mapping where genitourinary capital is concentrating in the U.S., the revenue scale and funding depth in this directory give you a concrete starting point.
- ResearchAndMarkets.com
Ranked: Best Genitourinary Disorders companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Barinthus Biotherapeutics Developer of T-cell immunotherapeutics to treat multiple diseases | $210M | 29 mo ago | — | Adrian Hill Co-Founder | Public | 3 signals M&A · Earnings | 33 patents Peptide vaccine nanocarriers for cancer immunotherapy and targeted drug delivery | — |
| 2 | UroLift Minimally invasive BPH treatment, improving men's urological health and quality of life | $196M | 149 mo ago | 49 | — | Series D | — | — | — |
| 3 | Halt Medical Developer of a device for the removal of uterine fibroids | $188M | 147 mo ago | 24 | Jeff Cohen CEO | Series C | — | — | — |
| 4 | Axonics Developer of a device to control urinary and bowel movement | $143M | 98 mo ago | 762 | Raymond Cohen CEO | Acquired | — | 124 patents Implantable neurostimulation devices and MRI‑compatible leads with external pulse‑generator systems. | — |
| 5 | Neotract Minimally invasive devices in urology | $138M | 113 mo ago | 119 119 → 152 (+28%) | — | Acquired | — | 238 patents Minimally invasive therapeutic devices for urology and interventional procedures | — |
| 6 | AMB Developer of catheter system and technology for intensive care | $131M | 46 mo ago | 13 | Frank Gehres CEO | Series A | — | — | — |
| 7 | NeuSpera Medical Miniaturized neurostimulation devices | $125M | 23 mo ago | 39 | — | Series D | — | — | — |
| 8 | Spero Therapeutics Developer of therapeutics for drug-resistant bacterial infections | $115M | 43 mo ago | 147 | Milind Deshpande Co-Founder and Board member | Public | — | 149 patents Oral carbapenem formulations and novel polymyxin derivatives for resistant bacterial infections | — |
| 9 | Fulcrum Therapeutics Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | $115M | 72 mo ago | 104 104 → 65 (-38%) | Robert Gould CEO | Public | 7 signals Announcements · IPO · Earnings | — | 1 job opening · 1 award |
| 10 | Taris Biomedical Innovative medicine, therapies, and medical technology for global healthcare solutions | $109M | 101 mo ago | 14 | Robert Langer Co-Founder | Acquired | — | 720 patents Implantable urological drug‑delivery systems for localized gemcitabine bladder cancer therapy | — |
| 11 | TELA Bio Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction | $105M | 83 mo ago | 173 | Antony Koblish Co-Founder and CEO | Public | 12 signals ▼40% Earnings · Funding · Leadership | — | — |
| 12 | VenatoRx US-based, clinical stage biotech developing beta-lactamase inhibitors for DR infections 50Funding top 19%Product top 25%Innovation top 34%Growth top 39% All 9 signals ▾Fundingtop 19% Producttop 25% Innovationtop 34% Growthtop 39% Moattop 39% Marketbottom 40% Globalbottom 37% Newsbottom 27% Techbottom 25% Funding: Raised $103M across 35 rounds · 35 rounds over 13 yrs (2.7/yr) Product: 8 distinct product lines · Company stage: Series C rank vs industry peers · Fliar Intelligence Index 50/100 | $103M | 12 mo ago | 80 | — | Series C | — | — | — |
| 13 | Sumitomo Developer of therapies for treating urological disorders | $100M | 87 mo ago | 313 | — | Public | — | — | — |
| 14 | Outpost Medicine Developer of therapeutics for the treatment of urologic and gynecologic disorders | $97M | 103 mo ago | 4 | — | Deadpooled | — | — | — |
| 15 | Francis Medical Developer of a therapeutic solution to treat prostate, kidney, and bladder cancer | $77M | 18 mo ago | 29 | — | Series C | — | — | 2 launchs |
| 16 | Bright Uro Developer of a device for the diagnosis of lower urinary tract diseases | $65M | 12 mo ago | 8 | Derek Herrera Founder - CEO | Series A | — | — | 2 partnerships · 1 expansion |
| 17 | Renovia Developer of e-stimulation device and tools for the strengthening of pelvic floor muscles | $57M | 62 mo ago | 19 | Eileen Maus CEO | Series C | — | 59 patents Patents concentrated in health & consumer products | — |
| 18 | Zenflow Developer of device to treat urinary obstruction related to BPH | $55M | 19 mo ago | 25 25 → 42 (+68%) | Shreya Mehta ex-Co-Founder & CEO | Series C | — | 69 patents Precise implantation and imaging devices for prostatic urethra treatments | — |
| 19 | Amphora Medical Radiofrequency ablation device for overactive bladder treatment | $48M | 106 mo ago | 12 | — | Series B | — | — | — |
| 20 | Urotronic Developer of smart devices for treating urethral stricture | $47M | 68 mo ago | 18 | — | Acquired | — | 93 patents Drug‑coated balloon catheters for localized therapeutic delivery in vascular and non‑vascular lumens | — |
| 21 | Signostics Provider of POC ultrasound device to calculate bladder volume | $44M | 127 mo ago | 112 | Stewart Bartlett Co-Founder & COO | Series B | — | — | — |
| 22 | Sonomotion Developer of a non-invasive medical device for kidney stone treatment | $42M | 13 mo ago | 9 | Bryan Cunitz Co-Founder | Series C | — | 8 patents Focused ultrasonic propulsion probes and radiation-force control for therapeutic ultrasound applications | — |
| 23 | Avation Developer of wearable device for at-home treatment of overactive bladder symptoms | $35M | 28 mo ago | 24 | Manish Vaishya Co-Founder & CTO | Series C | 4 signals ▲300% Contracts · Acquisition | — | — |
| 24 | Rivermark Developer of medical device for treatment of benign prostatic hyperplasia | $34M | 1 mo ago | 5 | Andy Doraiswamy Co-Founder & Chairman | Series D | — | — | — |
| 25 | Levee Medical Developer of urological devices for post-prostatectomy | $27M | 4 mo ago | 3 | Bruce Choi Founder & CTO | Series B | — | — | — |
| 26 | Applaud Medical Revolutionary kidney stone treatment without anesthesia, stents, expanding global access | $25M | 64 mo ago | 17 | Claire Mills Co-Founder | Series A | — | — | — |
| 27 | Cogentix Medical Minimally invasive treatment of voiding dysfunctions and endoscopy solution | $25M | 117 mo ago | 141 | — | Acqui-Hired | — | — | — |
| 28 | Genefluidics Electrochemical sensor for rapid diagnosis of urinary tract infections (UTIs) | $23M | 133 mo ago | 6 | — | Funding Raised | — | 60 patents Rapid phenotypic antimicrobial susceptibility testing and electrokinetic sample handling | — |
| 29 | Valencia Technologies Developer of a coin-sized pacemaker-like device for the treatment of hypertension | $22M | 15 mo ago | 69 | Jeff Greiner Founder | Acquired | — | 57 patents Implantable electroacupuncture neuromodulation devices for metabolic and cardiovascular therapy | — |
| 30 | Contraline Developer of a male contraceptive hydrogel device | $19M | 9 mo ago | 7 | Kevin Eisenfrats Co-Founder & CEO | Series A | — | 55 patents Implantable, stimuli‑responsive drug delivery systems for male contraception and biomaterial therapeutics | 1 job opening |
| 31 | TAS Medical Provider of solution to assist in laparoscopic hernia repair | $19M | 2 mo ago | 8 | Albert Chin Co-Founder | Series A | — | — | — |
| 32 | Deep Blue Medical Advance Developer of hernia mesh devices for treating hernia | $13M | 9 mo ago | 12 | — | Series A | — | — | — |
| 33 | TheraVida Developing innovative therapies for hyperhidrosis, improving patient lives | $13M | 39 mo ago | 2 | Ben McGraw CEO & Chairman | Series A | — | 157 patents Pharmaceutical formulations for treating hyperhidrosis and overactive bladder conditions. | — |
| 34 | Aurie Developer of an automated reusable self-catheter system | $12M | 26 mo ago | 4 | Marjorie Nelson Co-Founder | Series A | — | — | — |
| 35 | Sandstone Diagnostics Provider of rapid test for sperm count | $12M | 85 mo ago | 14 | — | Deadpooled | — | 43 patents Portable point‑of‑care blood centrifugation and plasma separation devices for rapid diagnostics | — |
| 36 | NanoVibronix Provider of ultrasound therapy devices for multiple health purposes | $11M | 11 mo ago | 10 | Harold Jacob CEO | Public | — | 35 patents Ultrasonic surface acoustic wave devices for skin therapy, drug delivery, and biofilm control | — |
| 37 | Function Promoting Therapies Developer of diagnostic tools and sustained testosterone delivery systems | $9M | 14 mo ago | — | Satish Vankayalapati Founder | Funding Raised | — | 13 patents Diagnostic and therapeutic systems for androgen and sex hormone disorder detection and treatment | — |
| 38 | cathBuddy Limited information available | $8M | 16 mo ago | — | Souvik Paul Founder & CEO | Series A | — | 18 patents Portable sterilization and containment solutions for reusable urinary catheters | — |
| 39 | Swan Valley Medical Provider of urological surgical instruments | $7M | 8 mo ago | 6 | Ronald Zook President & CEO | Series A | — | — | — |
| 40 | Ariste Medical Drug eluting surgical implants to prevent device failure | $7M | 63 mo ago | 6 | — | Series A | — | — | — |
| 41 | Minnesota Medical Technologies Provider of medical technology services for people suffering from incontinence | $7M | 6 mo ago | 15 | David Jonas CEO | Series A | 3 signals Funding | — | — |
| 42 | NEXT Life Sciences Developer of male contraception procedures | $4M | 29 mo ago | 2 | L Fox Founder & CEO | Seed | — | — | — |
| 43 | Vivifi Medical Developer of a minimally-invasive device to treat prostatic hyperplasia male infertility | $4M | 13 mo ago | 2 | Tushar Sharma Founder & CEO | Funding Raised | — | — | — |
| 44 | CollaMedix Developer of device for treating urinary incontinence in women | $4M | 33 mo ago | 8 | Donna Richardson CEO | Funding Raised | — | — | — |
| 45 | Lipella Developer of lipid-based therapies for common bladder syndromes | $3M | 10 mo ago | 5 | — | Public | — | — | — |
| 46 | Alessa Therapeutics Developer of localized, sustained drug delivery systems for prostate diseases. | $3M | 14 mo ago | 13 | Pamela Munster Founder & Director | Series A | — | — | 1 award |
| 47 | Elidah Provider of non-invasive home device for strengthening pelvic muscles control | $3M | 36 mo ago | 7 | Gloria Kolb Co-Founder & CEO | Seed | — | 15 patents Electrical stimulation devices for urinary incontinence therapy | 1 launch · 1 award |
| 48 | Plan A Provider of a non-hormonal and reversible male contraception solution | $2M | 29 mo ago | — | L Fox CEO | Seed | — | 32 patents Patents concentrated in computing, sensing & instrumentation | — |
| 49 | Strauss Surgical Innovating minimally invasive surgical solutions with high-definition endoscopes and instruments | $2M | 25 mo ago | — | — | Seed | — | — | 2 launchs |
| 50 | Urolution Developer of foley catheters for drainage mechanism of urine | $200K | 22 mo ago | — | Shaolong Qu Co-Founder | Seed | — | — | — |
Top 12 Genitourinary Disorders companies in United States
#1
Series D · Milwaukee, Wisconsin · founded 2021 · 5 employees$34.2Mraised▾
Developer of medical device for treatment of benign prostatic hyperplasia. It offers minimally invasive device FloStent which consist of a nitinol stent that holds the prostatic urethra open to restore normal urinary function.
- May 2026Series D$20M
- Sep 2024Series C$30M
- Jul 2023Series A$4.1M
#2
Series A · Windermere, Florida · founded 2017 · 8 employees$18.6Mraised▾
Provider of solution to assist in laparoscopic hernia repair. Its product Trans Abdominal Strap assists in reducing the need for invasive surgical procedures and use of mesh for hernia treatment. It has surgical-grade zip straps are allowing surgeons to convert complex abdominal hernias from open surgery to robotic surgery.
- Mar 2026Series A$3.9M
- Aug 2024Series A$4.2M
- Nov 2022Series A$3.2M
- Nov 2020Series A$5.2M
#3
Series B · Durham, North Carolina · founded 2021 · 3 employees$27.4Mraised▾
Developer of urological devices for post-prostatectomy. It offers VORO urological scaffold a bioresorbable device for urinary incontinence in radical prostatectomy patients. It optimizes and reduces complications associated with surgical treatment.
- Feb 2026Series B$12M
- Oct 2025Conventional Debt$12.5M
- Feb 2025Series B$14M
- Sep 2023Series A$4.3M
#4
Series C · Malvern, Pennsylvania · founded 2010 · 80 employees$102.7Mraised▾
VenatroRx is a US-based, clinical stage biotech developing beta-lactamase inhibitors for DR infections. The company focuses on beta-lactamase inhibitors that target penicillin binding proteins to overcome bacterial resistance to beta-lactam drugs. Their lead candidate, VNRX‐5133, is an intravenous beta‐lactamase inhibitor. VNRX‐5133 is designed to inhibit the four major classes of beta‐lactamase resistance enzymes, including metallo‐beta‐lactamases (MBL). VenatoRx plans to use the drug to inhibit bacterial resistance mechanisms, enabling a paired beta-lactam antibiotic to kill the microorganisms. The other candidate is VNRX‐7145, an orally bioavailable beta‐lactamase inhibitor that is in late preclinical testing. In Jul.2017, the company was awarded $9.4M from CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator)
- May 2025Grant (prize money)$6.3M
- May 2025Grant (prize money)$3M
- Apr 2025Grant (prize money)$2M
- Feb 2025Grant (prize money)$7.4M
#5
Series A · Aliso Viejo, California · founded 2021 · 8 employees$65.3Mraised▾
Developer of a device for the diagnosis of lower urinary tract diseases. It offers a Glean Urodynamics System consisting of an insertion tool, a Bluetooth-enabled pressure sensor in a flexible silicone tube, a software app, and a uroflowmeter to sense volume and flow.
- Jun 2025Series A$15M
- Jun 2025Series A$14.7M
- Jan 2025Grant (prize money)$1.8M
- Oct 2024Series A$32M
#6
Series A · Charlottesville, Virginia · founded 2015 · 7 employees$18.6Mraised▾
Developer of a male contraceptive hydrogel device. The ADAM is a non-surgical, non-hormonal, and reversible birth control for men. It isultrasound-visible polymer solution that is injected into the vas deferens. Echo-V& forms a hydrogel device that acts as a semi-permeable membrane, blocking sperm while allowing fluids through.
- Sep 2025Grant (prize money)$1.4M
- Sep 2024Grant (prize money)$291.4K
- Nov 2022Series A$7.2M
- Oct 2021Series A$10.7M
#7
Series C · San Mateo, California · founded 2014 · 9 employees$41.8Mraised▾
Developer of a non-invasive medical device for kidney stone treatment. The products of the company include Break Wave an ultrasound solution that fragments kidney stones non-invasively and Stone Clear a non-invasive ultrasound-based tool to reposition kidney stones within the kidney and ureter.
- Apr 2025Grant (prize money)$2.2M
- Feb 2025Grant (prize money)$278.2K
- Nov 2022Series C$12.4M
- Apr 2022Series B$11.5M
#8
Series A · Stewartville, Minnesota · founded 2015 · 15 employees$6.5Mraised▾
Provider of medical technology services for people suffering from incontinence
- Dec 2025Series A$20.6M
- Oct 2024Series A$2.5M
- Aug 2023Series A$4.4M
- Jan 2023Seed$2.1M
#9
Series A · Durham, North Carolina · founded 2015 · 12 employees$12.9Mraised▾
Deep Blue is involved in developing a hernia mesh to address the high rate of hernia occurrence and recurrence. They have developed T-Line mesh and Anchor Clips that have the potential to reduce hernia occurrence and recurrence.
- Sep 2025Series A$5.6M
- Jun 2022Series A$7M
- Feb 2021Series A$3.4M
- Jan 2021Series A$1.6M
#10
Series C · Maple Grove, Minnesota · founded 2018 · 29 employees$77Mraised▾
Developer of a therapeutic solution to treat prostate, kidney, and bladder cancer. The company has developed a convective water vapor energy technology that is applied to deliver targeted treatments to the cancerous prostate tissue.
- Dec 2024Series C$80M
- Sep 2021Series B$55M
- Sep 2020Series A$4M
- Dec 2018Series A$18M
#11
Series A · Bigfork, Montana · founded 2006 · 6 employees$6.8Mraised▾
Provider of urological surgical instruments. The company focused on development and commercialization of urological surgical instruments incorporating new approaches and technologies to enhance and improve upon existing surgical devices and procedures. Its products comprise T-SPeC, a disposable instrument for suprapubic bladder catheterization; and LithoPro, a single-use instrument that creates unobstructed 40 Fr. suprapubic access to the bladder for the removal of bladder calculi (cystolithotripsy), as well as to provide drainage and removal of tissue fragments during procedures for benign prostatic hyperplasia.
- Oct 2025Series A$100K
- Jul 2024Series A$40K
- May 2023Series A$100K
- Apr 2022Series A$40K
#12
Series D · Santa Clara, California · founded 2014 · 39 employees$124.6Mraised▾
NeuSpera is developing miniaturized injectable neuromodulation technologies. The company aims to create implantable devices to treat chronic diseases. As of 2015, NeuSpera had received regulatory approvals for 3 implantable neuromodulation devices and a 4th wearable device that provides remote monitoring of patients with epilepsy. One of these new products contains a fundamental advancement to the company’s core therapy – Closed-Loop Vagus Nerve Stimulation Therapy for epilepsy while two others enable the company to enter into two large markets – Heart Failure and Mobile Health.
- Jul 2024Series D$23M
- Jun 2021Series C$65.7M
- Jan 2018Series B$26M
- Jun 2016Series A$8.9M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genitourinary Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.